Commitments include more than 400 million dose units across Europewith 125 million devices delivered to date
EYSINS, Switzerland, Dec. 17, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to support global COVID-19 vaccination planning efforts.
This milestone reflects 400 million dose units committed to countries across Europe, including Belgium, France, Germany, Netherlands, Spain and the United Kingdom, among several others. It also reflects governments around the world, including the United States, Australia, Canada and Saudi Arabia, as well as non-governmental organizations supporting vaccine deployment for developing countries.
Shipments are already underway and more than 300 million injection devices have been delivered around the world to date, including 125 million in Europe, with the remaining orders to be delivered between now and the end of 2021 to support vaccine administration. A vast majority of the needles and syringes for Europe are being produced in two of BD’s manufacturing facilities in Europe. These devices are then shipped to governments or appointed distribution partners where they will then be distributed to health care facilities based on each country’s individual distribution and allocation strategy. BD continues to be in discussions with governments and non-governmental organizations on the need to place orders immediately for delivery later in calendar year 2021 and 2022.
“This milestone is more than just a number – it represents hundreds of millions of people in Europe and around the world, such as frontline workers and at-risk loved ones who will now be able to receive a vaccination the moment vaccines are available,” said Roland Goette, executive vice president and president of Europe, Middle East and Africa for BD. “We commend our government partners across Europe for taking proactive steps to protect their populations. We will continue to collaborate to ensure timely deployment of vaccination campaigns to overcome this virus. From our decades of immunization experience, we also know our work doesn’t stop at delivery. We are equally committed to providing resources to ensure health care communities in Europe have the right training tools and support on injection techniques to implement these campaigns.”
The company continues to closely plan supply capabilities to ensure maximum volumes can be dedicated to COVID-19 efforts while minimizing disruption for routine health care and annual flu vaccination and childhood immunization programs.
In addition to supporting immediate efforts for COVID-19 vaccination readiness, BD is also working on multiple fronts to help ensure the global community is prepared for future pandemic vaccination efforts by:
BD is the largest manufacturer of injection devices in the world, producing billions of syringes and needles annually through its global manufacturing network. Learn more about BD’s vaccination preparedness efforts at bd.com/vaccination.
In addition to ramping up manufacturing of needles and syringes, BD has been working closely with governments and multilateral organizations around the world to expand access to diagnostic testing and support treatment of COVID-19 patients. The company has supplied health care providers globally with millions of products used in of the fight against COVID-19, including swabs for flu and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus System, infusion pumps, infusion sets and catheters. BD Biosciences instruments are also being used by researchers around the world to better understand the human immune response to COVID-19.
About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
Forward-Looking StatementsThis press release contains certain forward-looking statements regarding BD’s manufacturing operations. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, many of which are beyond the company’s control. BD expressly disclaims any undertaking to update any such statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.
Logo – https://mma.prnewswire.com/media/617615/BD_Logo.jpg
